buy sell hold  

PHILLIP SECURITIES UOB KAYHIAN

iX Biopharma Ltd – Multiple share price catalyst

 

  • Outlicensing of Wafermine for Phase 3 trials is a major share price catalyst for the company to enter the estimated US$19bn global opioid industry.
  • Plans for a Hong Kong IPO could trigger a price discovery of at least a HK$1.5bn (S$260mn) market valuation for the pharmaceutical business.
  • Our earnings forecast cut to a net loss in FY22e due to delay in new capacity. Our BUY recommendation is maintained. Our DCF (WACC 10%) TP is lowered to S$0.335 from S$0.445 following our earnings downgrade and rights issue.

 

Read More ...

 

Sembcorp Industries (SCI SP)

Towards A Brighter And Greener Future

 

SCI presented at the Asian GEMS conference and highlighted its medium - to long-term plan to transition towards being a greener and more sustainable business. Near-term issues such as India’s power crisis and maintenance shutdowns at some power assets appear to be well understood by the market. Maintain BUY. Target price: S$2.59.

 

Read More ...

MAYBANK KIM ENG

CGS CIMB

Singapore Banks

Balance sheet balancing

 

Deploying liquidity could be a strategic advantage

Singapore banks are sitting on massive liquidity. How they deploy could determine profitability on the other side of COVID. DBS has been mostly parking excess at central banks, while UOB has increased its securities holdings. For the latter, this may provide a near-term margin boost. Ultimately, higher lending is the most desired option, but varying speeds of re-opening cloud near-term visibility. Yet, we expect ASEAN-5 growth to surge (+5.6% GDP) in 2022E, which should give the sector significant opportunities to participate – particularly with SMEs. UOB with stronger ASEAN integration and SME franchise could benefit the most, in our view.

 

Read More ...

 

 

Ascendas REIT

Improving operating metrics

 

■ Positive rental reversions and higher portfolio occupancy in 3Q21.

■ Strong balance sheet with aggregate leverage at 37.4% at end-3Q21 provides room for inorganic growth.

■ Reiterate Add with an unchanged DDM-based TP of S$3.31. 3Q21 business update In its 3Q21 business update, AREIT reported an improvement in portfolio occupancy to 91.7%, with higher take-up in Singapore, Australia and UK/Europe, partly offset by a slight drag in the US. Rental reversion averaged +3.7% in 3Q and +5.4% YTD. Aggregate leverage stood at 37.4% at end-3Q21, translating to an available debt headroom of S$4.2bn, based on a 50% limit, to pursue inorganic growth opportunities. AREIT has S$389.3m worth of asset enhancement initiatives currently underway in Singapore and Australia, scheduled to complete between 4Q21 and 4Q23.

 

Read More ...



LionelLim8.16Check out our compilation of Target Prices



You may also be interested in:


You have no rights to post comments

Counter NameLastChange
AEM Holdings1.840-0.020
Best World2.480-
Boustead Singapore0.950-0.005
Broadway Ind0.1450.005
China Aviation Oil (S)0.865-0.005
China Sunsine0.390-0.005
ComfortDelGro1.390-0.010
Delfi Limited0.875-
Food Empire1.120-0.010
Fortress Minerals0.310-
Geo Energy Res0.3000.005
Hong Leong Finance2.420-0.010
Hongkong Land (USD)3.4200.010
InnoTek0.505-
ISDN Holdings0.300-0.005
ISOTeam0.047-
IX Biopharma0.039-0.004
KSH Holdings0.245-
Leader Env0.049-
Ley Choon0.055-0.001
Marco Polo Marine0.068-0.003
Mermaid Maritime0.1350.002
Nordic Group0.305-
Oxley Holdings0.0900.001
REX International0.124-
Riverstone0.9300.005
Southern Alliance Mining0.480-
Straco Corp.0.490-
Sunpower Group0.230-
The Trendlines0.063-
Totm Technologies0.019-0.002
Uni-Asia Group0.810-0.035
Wilmar Intl3.160-
Yangzijiang Shipbldg1.750-0.020
 

We have 327 guests and no members online

rss_2 NextInsight - Latest News